A new virus that is triggering another worldwide health calamity has emerged while the COVID-19 epidemic unfolds. Approximately 100 countries have already experienced the spread of Monkeypox, which has affected 50,000 individuals globally. Scientists have been working on several medications and have created vaccines for testing, but there is still no known cure.

The Monkeypox virus, a member of the smallpox virus family, is the infectious illness that causes Monkeypox. Most often, it is transmitted by direct personal contact with an infected person. Typical symptoms include everything from fevers to a minor rash that eventually turns into blisters. The illness typically gets better with time, although it can take a very long time and have negative repercussions. A global health emergency has been declared due to the virus' ongoing global spread. The recuperation process is currently being sped up through research into therapy options.

Image: https://www.nationalgeographic.co.uk/science-and-technology/2022/05/monkeypox-cases-are-rising-heres-what-we-know-so-far

The medicine Tecovirimat, also known as Tpoxx, is being used in a study created by researchers at the University of Oxford to speed up recovery from Monkeypox. After some promising outcomes from research on both humans and animals, Tecovirimat received a license for the treatment of Monkeypox. With the use of this license, University of Oxford researchers will examine a population of 500 patients, with half of them receiving Tecovirimat tablets twice daily and the other half receiving placebo tablets. Researchers want to learn more about the medicine and how to treat Monkeypox through this trial. Tecovirimat has already been used to treat people with severe Monkeypox. In other interviews, patients have stated that they feel healthier and more optimistic about fully recovering from Monkeypox.

이예인 강남포스트 학생기자  webmaster@ignnews.kr

<저작권자 © 강남포스트, 무단 전재 및 재배포 금지>